Gaps in US Psychedelic Policy and How to Close Them
Caleigh Propes, Katherine Cheung, Matthew D. Eisenberg, David B. Yaden
JAMA Health Forum November 7, 2025 DOI: 10.1001/jamahealthforum.2025.4928 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Viewpoint Peer reviewed |
|---|---|
| Topics | Addiction |
| Keywords | Mental health Government linguistics Public policy Action physics Substance use Criminology Public relations |
| Citations | 4 |
| Key points | Policy gaps surrounding the use of psychedelics for mental health and substance use conditions need to be addressed before and after potential FDA approval. |
Abstract
This Viewpoint discusses how to fill policy gaps surrounding the use of psychedelics to treat mental health and substance use conditions, should they be approved by the US Food and Drug Administration.